Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment

Fujian Haixi Pharmaceuticals

05/08/2026 05:52

** Shares of Fujian Haixi Pharmaceuticals  2637.HK  jump 14.5%
in the fourth straight rising session to HK$213.4, their highest
level since July 10
    ** Stock on track for the biggest one-day pct rise since
April 27, if gains hold
** China-based generic and innovative drugs developer says U.S.
Food and Drug Administration (FDA) approves Investigational New
Drug Application (IND) of company's HX9428 for treatment of
neovascular age-related macular degeneration (nAMD)
    ** Company says it officially commences the second Phase II
clinical trial of HX9428 for the treatment of nAMD in
    China
    ** YTD, stock up 49.4%, Hang Seng Biotech Index  .HSBIO  up
0.5%
     

(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))